Drug General Information |
Drug ID |
D07LRJ
|
Former ID |
DNC003657
|
Drug Name |
SB-271046
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C20H22ClN3O3S2
|
InChI |
InChI=1S/C20H22ClN3O3S2/c1-13-16-11-14(21)3-6-19(16)28-20(13)29(25,26)23-15-4-5-18(27-2)17(12-15)24-9-7-22-8-10-24/h3-6,11-12,22-23H,7-10H2,1-2H3
|
InChIKey |
LOCQRDBFWSXQQI-UHFFFAOYSA-N
|
PubChem Compound ID |
|
PubChem Substance ID |
7980575, 11056907, 14906583, 39341767, 47285909, 48329098, 53338758, 57359529, 58097771, 85209290, 103199108, 103988997, 114158005, 126522428, 128517213, 131549286, 134340862, 135651001, 142034489, 162009826, 162223692, 164024753, 172914471, 186000965, 226553455, 252473346
|
Target and Pathway |
Target(s) |
D(3) dopamine receptor |
Target Info |
Inhibitor |
[2]
|
5-hydroxytryptamine 6 receptor |
Target Info |
Inhibitor |
[3]
|
Dopamine D1 receptor |
Target Info |
Inhibitor |
[2]
|
5-hydroxytryptamine 2A receptor |
Target Info |
Inhibitor |
[2]
|
5-hydroxytryptamine 1A receptor |
Target Info |
Inhibitor |
[2]
|
D(4) dopamine receptor |
Target Info |
Inhibitor |
[2]
|
5-hydroxytryptamine 7 receptor |
Target Info |
Inhibitor |
[2]
|
D(2) dopamine receptor |
Target Info |
Inhibitor |
[2]
|
5-hydroxytryptamine 2C receptor |
Target Info |
Inhibitor |
[2]
|
KEGG Pathway
|
Neuroactive ligand-receptor interaction
|
Dopaminergic synapsehsa04020:Calcium signaling pathway
|
cAMP signaling pathway
|
Serotonergic synapsehsa04020:Calcium signaling pathway
|
Gap junction
|
Dopaminergic synapse
|
Parkinson's disease
|
Cocaine addiction
|
Amphetamine addiction
|
Morphine addiction
|
Alcoholismhsa04020:Calcium signaling pathway
|
Serotonergic synapse
|
Inflammatory mediator regulation of TRP channelshsa04024:cAMP signaling pathway
|
Serotonergic synapsehsa04080:Neuroactive ligand-receptor interaction
|
Dopaminergic synapsehsa04014:Ras signaling pathway
|
Calcium signaling pathway
|
Serotonergic synapsehsa04015:Rap1 signaling pathway
|
Inflammatory mediator regulation of TRP channels
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP05912:Dopamine receptor mediated signaling pathwayP04374:5HT2 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
5HT1 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
Dopamine receptor mediated signaling pathway
|
Nicotine pharmacodynamics pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Nicotine pharmacodynamics pathwayP04374:5HT2 type receptor mediated signaling pathway
|
PathWhiz Pathway
|
Excitatory Neural Signalling Through 5-HTR 6 and SerotoninPW000440:Dopamine Activation of Neurological Reward SystemPW000443:Excitatory Neural Signalling Through 5-HTR 7 and Serotonin
|
Reactome
|
Dopamine receptors
|
G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors
|
G alpha (s) signalling eventsR-HSA-390651:Dopamine receptors
|
G alpha (s) signalling eventsR-HSA-390666:Serotonin receptors
|
G alpha (q) signalling eventsR-HSA-390666:Serotonin receptors
|
G alpha (i) signalling eventsR-HSA-390651:Dopamine receptors
|
G alpha (q) signalling events
|
WikiPathways
|
Monoamine GPCRs
|
GPCRs, Class A Rhodopsin-like
|
GPCR ligand binding
|
GPCR downstream signaling
|
Nicotine Activity on Dopaminergic Neurons
|
GPCRs, OtherWP734:Serotonin Receptor 4/6/7 and NR3C Signaling
|
GPCR downstream signalingWP666:Hypothetical Network for Drug Addiction
|
Genes and (Common) Pathways Underlying Drug Addiction
|
GPCR downstream signalingWP733:Serotonin Receptor 2 and STAT3 Signaling
|
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
|
SIDS Susceptibility Pathways
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
GPCRs, OtherWP722:Serotonin HTR1 Group and FOS Pathway
|
GPCRs, OtherWP666:Hypothetical Network for Drug Addiction
|
Nicotine Activity on Dopaminergic NeuronsWP732:Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
|
References |
REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 276). |
---|
REF 2 | Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43. Epub 2007 Nov 17.Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. |
---|
REF 3 | Bioorg Med Chem Lett. 2009 May 1;19(9):2409-12. Epub 2009 Mar 25.Synthesis and SAR of tolylamine 5-HT6 antagonists. |